629
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Investigation of maternal serum endocan concentrations in pregnant women with gestational diabetes mellitus; a prospective case-control study

ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Article: 2254889 | Received 25 May 2023, Accepted 29 Aug 2023, Published online: 10 Sep 2023

References

  • Johns EC, Denison FC, Norman JE, et al. Gestational diabetes mellitus: mechanisms, treatment, and complications. Trends Endocrinol Metab. 2018;29(11):743–754. doi:10.1016/j.tem.2018.09.004.
  • O’sullivan JB, Mahan CM. Criteria for the oral glucose tolerance test ın pregnancy. Diabetes. 1964;13:278–285.
  • Akgol S, Obut M, Baglı İ, et al. An evaluation of the effect of a one or two-step gestational diabetes mellitus screening program on obstetric and neonatal outcomes in pregnancies. Gynecol Obstet Reprod Med. 2019;25(2):62–66. doi:10.21613/GORM.2018.791.
  • International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676–682.
  • Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Geneva: World Health Organization; 2013 [cited 2023 Mar 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK169024/.
  • Lassalle P, Molet S, Janin A, et al. ESM-1 Is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458–20464. doi:10.1074/jbc.271.34.20458.
  • Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765(1):25–37. doi:10.1016/j.bbcan.2005.08.004.
  • Balta S, Balta I, Mikhailidis DP. Endocan: a new marker of endothelial function. Curr Opin Cardiol. 2021;36(4):462–468. doi:10.1097/HCO.0000000000000867.
  • Pan K-F, Yang Y-C, Lee W-J, et al. Proteoglycan endocan: a multifaceted therapeutic target in cancer. Biochim Biophys Acta Rev Cancer. 2022;1877(1):188672. doi:10.1016/j.bbcan.2021.188672.
  • De Freitas Caires N, Gaudet A, Portier L, et al. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22(1):280. doi:10.1186/s13054-018-2222-7.
  • Chew BS, Ghazali R, Othman H, et al. Endocan expression in placenta of women with hypertension: endocan expression in placenta. J Obstet Gynaecol Res. 2019;45(2):345–351. doi:10.1111/jog.13836.
  • Chang X, Bian Y, Wu Y, et al. Endocan of the maternal placenta tissue is increased in pre-eclampsia. Int J Clin Exp Pathol. 2015;8:14733–14740.
  • Murthi P, Sarkis R, Lim R, et al. Endocan expression is increased in the placenta from obese women with gestational diabetes mellitus. Placenta. 2016;48:38–48. doi:10.1016/j.placenta.2016.10.003.
  • Anık A, Çelik E, Çevik Ö, et al. The relation of serum endocan and soluble endoglin levels with metabolic control in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2020;33(8):1013–1018. doi:10.1515/jpem-2020-0146.
  • Arman Y, Akpinar TS, Kose M, et al. Effect of glycemic regulation on endocan levels in patients with diabetes: a preliminary study. Angiology. 2016;67(3):239–244. doi:10.1177/0003319715585664.
  • Sezer H, Yazici D, Canbaz HB, et al. The frequency of acceptance of oral glucose tolerance test in Turkish pregnant women: a single tertiary center results. North Clin Istanb. 2022;9(2):140–148. https://northclinist.com/jvi.aspx?un=NCI-80588&volume=. doi:10.14744/nci.2021.80588.
  • Andrade HdA, Pedrosa W, Diniz MdF, et al. Adverse effects during the oral glucose tolerance test in post-bariatric surgery patients. Arch Endocrinol Metab. 2016;60(4):307–313. doi:10.1590/2359-3997000000149.
  • Iozzo RV, Schaefer L. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol. 2015;42:11–55. doi:10.1016/j.matbio.2015.02.003.
  • Rocha SF, Schiller M, Jing D, et al. Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res. 2014;115(6):581–590. doi:10.1161/CIRCRESAHA.115.304718.
  • Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. doi:10.1186/s12933-018-0763-3.
  • Klisic A, Kavaric N, Vujcic S, et al. Inverse association between serum endocan levels and small LDL and HDL particles in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2020;24:8127–8135.
  • Mercantepe F, Baydur Sahin S, Cumhur Cure M, et al. Relationship between serum endocan levels and other predictors of endothelial dysfunction in obese women. Angiology. 2022;1–10. doi:10.1177/00033197221129358.
  • Nalbantoğlu A, Kızılca Ö, Güzel S, et al. Increased carotid ıntima–media thickness and endothelial cell-specific molecule-1 (endocan) levels in obese children. Angiology. 2021;72(7):633–639. doi:10.1177/0003319721995664.